Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2828198 | 0.87 | PIM1 (0.40) | ACMSDKDM4EMAPTNFE2L2ALDH1A1 | |
| SCHEMBL2828199 | 0.87 | PIM1 (0.40) | ACMSDKDM4EMAPTNFE2L2ALDH1A1 | |
| SCHEMBL2824658 | 0.82 | MPL (0.35) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL2824763 | 0.81 | ACMSD (0.38) | ACMSDKDM4EMAPTNFE2L2ALDH1A1 | |
| SCHEMBL2824759 | 0.81 | ACMSD (0.38) | ACMSDKDM4EMAPTNFE2L2ALDH1A1 | |
| SCHEMBL2827667 | 0.77 | MAPK1 (0.48) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL2823729 | 0.77 | PIM1 (0.40) | KDM4EHSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL2823725 | 0.77 | PIM1 (0.40) | KDM4EHSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL2827670 | 0.77 | MAPK1 (0.48) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL2827321 | 0.74 | MPL (0.33) | KDM4EALDH1A1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318928-B2 | Fused imidazole carboxamides as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | ACMSD 1516/4885KDM4E 3190/4885MAPT 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.